Hormonal
Gut microbiota dysbiosis in obesity contributes to low-grade inflammation and increased fat storage through mechanisms including increased gut permeability (leaky gut), systemic lipopolysaccharide (LPS) circulation, and altered signaling of satiety hormones (GLP-1, PYY, ghrelin) via the gut-brain axis.
Focus on dietary fiber and diverse plant foods to support a healthy gut microbiome, which may help regulate satiety hormones and reduce inflammation. While not a standalone cure, this biological lever supports overall metabolic health.
It is thought that changes in gut microbiota composition in obesity lead to increased gut permeability... Disruption of this intestinal barrier leads to passage of components, such as lipopolysaccharide (LPS)... into the systemic circulation. These elevated plasma levels of LPS can initiate inflammatory cascades... and can also induce neuroinflammation.
Why this rating
The paper is a review citing multiple human and animal studies, but notes inconsistencies and that many findings are associative rather than causal in humans.
Source
The Role of the Gut Microbiota in the Gut–Brain Axis in Obesity: Mechanisms and Future Implications
Jamie van Son et al. · International Journal of Molecular Sciences · 2021
DOI 10.3390/ijms22062993
More from this paper
- Fecal Microbiota Transplantation (FMT) from lean donors does not result in significant weight loss or improved metabolic health in humans with obesity, despite showing benefits in some animal models.Good
- Short-chain fatty acids (SCFAs) produced by gut microbiota from dietary fiber can influence satiety, energy expenditure, and glucose metabolism, but human trials on oral SCFA supplementation have shown mixed or null results for improving glucose metabolism or vagal tone.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →